Follow-up trial with no study drug prescription in diabetic patients previously included in the REGULATE trial To document the clinical condition of patients who were included in the REGULATE trial and exposed to the investigational drugs (benfluorex or pioglitazone).

• Country None
• organs None
• Specialty None

Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Disease patients with motor fluctuations: a 4-week open label pilot study Assessment of the acceptability of a sublingual formulation of piribedil

• Country None
• organs None
• Specialty None

A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19 To evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19.

• Country None
• organs None
• Specialty None

Evaluation of administration of gevokizumab versus placebo on the reduction of atheroma plaque inflammation ­The primary objective is to evaluate the effect of gevokizumab on arterial wall inflammation reduction following a recent Acute Coronary Syndrome (ACS)

• Country None
• organs None
• Specialty None

A study to evaluate the safety and tolerability of ascending doses of UCART19 given as a single infusion in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukaemia (ALL) and to determine the maximum tolerated dose (MTD) To evaluate the safety and tolerability of several doses of UCART19 in patient with relapsed/refractory (R/R) acute lymphoblastic leukaemia (ALL) and to determine the maximum tolerated dose (MTD).

• Country None
• organs None
• Specialty None

Long-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5/5/7.5 mg b.i.d.) on top of anti-anginal background therapy, to patients with chronic stable angina pectoris. An international, double-blind placebo controlled study - To document the absence of retinal toxicity of ivabradine versus placebo in chronic stable angina patients after treatment cessation in the subset of patients with emergent bilateral relevant ERG ab...

• Country None
• organs None
• Specialty None